Tracking Ankylosing Spondylitis Patients Receiving Combined Chinese and Western Medicine
Observes adults with ankylosing spondylitis receiving combined Chinese and Western treatment over time.
Plain-language title generated from the registry record
Registry title: Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Cohort Study
Key facts
- Where
- Beijing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with ankylosing spondylitis. It studies how combined Traditional Chinese and Western medicine affects daily function over 6 months.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- Ankylosing spondylitis, meeting the 1984 modified New York criteria, or axial spondyloarthritis meeting the 2009 ASAS classification criteria.
Main reasons for not taking part
- Another autoimmune disease, such as rheumatoid arthritis, Sjögren's syndrome, erythema nodosum or myositis
- Pregnancy or breastfeeding
- Severe heart or brain blood vessel disease, liver or kidney failure, or cancer
- Spondyloarthritis linked to bowel disease, psoriasis or reactive arthritis
- Unable to give data because of mental or language reasons
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07556224, who can take part
Where in China
- China-Japan Friendship HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- China-Japan Friendship Hospital
- Trial code
- NCT07556224
- Record updated
- 29 April 2026
- Original description
This study is a multicenter, prospective cohort study designed to systematically evaluate the clinical efficacy of integrated Traditional Chinese and Western Medicine on short-term functional improvement in patients with ankylosing spondylitis, with the Bath Ankylosing Spondylitis Functional Index (BASFI) at 6 months of treatment as the primary outcome measure.Read full original descriptionShow less
Evaluating the Efficacy and Short-Term Prognosis of Integrated Traditional Chinese and Western Medicine for Ankylosing Spondylitis(AS): A Protocol for a Prospective Multicenter Cohort Study
This study is a multicenter, prospective cohort study designed to systematically evaluate the clinical efficacy of integrated Traditional Chinese and Western Medicine on short-term functional improvement in patients with ankylosing spondylitis, with the Bath Ankylosing Spondylitis Functional Index (BASFI) at 6 months of treatment as the primary outcome measure.
Inclusion: fulfill the 1984 modified New York criteria for ankylosing spondylitis or the 2009 Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axial spondyloarthritis; age between 18 and 75 years; sign informed consent.
Exclusion: diagnosis of other autoimmune diseases besides the disease under investigation (e.g., rheumatoid arthritis, Sjögren's syndrome, erythema nodosum, myositis, etc.); comorbid severe cardiovascular or cerebrovascular diseases, hepatic or renal failure, or malignancy; pregnancy or lactation; spondyloarthritis related to enteropathic arthritis, psoriatic arthritis, or reactive arthritis; unable to provide data due to mental, language, or similar factors.